Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

SAVA Relative to the S&P 500

SAVA Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Cassava Sciences, Inc. (NASD:SAVA) seasonal charts above shows that a Buy Date of July 15 and a Sell Date of October 3 has resulted in a geometric average return of 12.2% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 32.07% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer’s disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer’s disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer’s disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.

To download SAVA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: SAVA